Lennox-Gastaut Syndrome (LGS) Clinical Trials and Treatments

Lennox-Gastaut Syndrome represents one of the most severe and intractable childhood epilepsies, often emerging from or following infantile spasms (West Syndrome). The characteristic EEG pattern shows slow (2.5 Hz or less) spike-and-wave activity, particularly evident during sleep. The syndrome is marked by multiple seizure types, with tonic seizures (brief stiffening episodes) being particularly characteristic, often occurring in clusters, especially during sleep.

The most common symptoms of Lennox-Gastaut Syndrome include Multiple seizure types: tonic-clonic, atonic (drop attacks), atypical absence, and focal seizures, Frequent clusters of seizures, sometimes hundreds per day, Intellectual disability and developmental regression, Speech and language delays, Behavioral disturbances including hyperactivity, aggression, and mood problems, among others. About 1-4% of childhood epilepsy cases, with about 2 new cases per 100,000 children each year (NORD). Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Lennox-Gastaut Syndrome from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Treatment of Lennox-Gastaut Syndrome remains challenging. The newest FDA approvals for LGS are cannabidiol (Epidiolex) in 2018 and fenfluramine (Fintepla) in March 2022, alongside older medicines such as rufinamide, clobazam, topiramate, lamotrigine and felbamate.

Yes. As of October 21, 2026, 8 FDA-approved medicines have a current label that names Lennox-Gastaut Syndrome: Banzel (rufinamide); Epidiolex (cannabidiol); Felbatol (felbamate); Fintepla (fenfluramine); Klonopin (clonazepam); Qudexy XR (topiramate); Subvenite (lamotrigine); and Sympazan (clobazam). Corticosteroids and immune globulins count once each.

Lennox-Gastaut Syndrome is caused by variants in any of many genes, most often SCN1A, STXBP1, CHD2, SCN8A, FOXG1 and GABRB3. Most cases follow a structural or acquired brain injury; when a genetic cause is found it is usually a de novo variant in one of many epilepsy genes, so panel or exome testing is used.

Most cases arise from a new variant not carried by either parent, so the chance of it recurring in a sibling is low but not zero. About 1-4% of childhood epilepsy cases, with about 2 new cases per 100,000 children each year (NORD). A multigene panel identifies the cause in most families.

Yes. Lennox-Gastaut Syndrome can be caused by variants in many different genes (SCN1A, STXBP1, CHD2, SCN8A, FOXG1 and GABRB3 are among the most common), so testing is usually a multigene panel or exome sequencing rather than one gene at a time. Most cases follow a structural or acquired brain injury; when a genetic cause is found it is usually a de novo variant in one of many epilepsy genes, so panel or exome testing is used.

Most cases arise from a new variant not carried by either parent, so the chance of it recurring in a sibling is low but not zero.

Knowing the exact gene matters: it decides which trials a patient qualifies for and which relatives should be tested. The labs currently offering the test are listed in the Genetic Testing section of this page, pulled live from the NIH Genetic Testing Registry. A genetic counselor can help interpret the result and decide which relatives should be tested.

Eligibility for Lennox-Gastaut Syndrome clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Lennox-Gastaut Syndrome clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.